cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Pardes Biosciences Inc
2 watching
Current Price
$1.71
$-0.07
(-3.93%)
logo-prds
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
101.08M
52-Week High
52-Week High
13.135
52-Week Low
52-Week Low
0.75
Average Volume
Average Volume
0.1M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization101.08M
icon52-Week High13.135
icon52-Week Low0.75
iconAverage Volume0.1M
iconDividend Yield--
iconP/E Ratio--
What does the Pardes Biosciences Inc do?
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Read More
How much money does Pardes Biosciences Inc make?
News & Events about Pardes Biosciences Inc.
Globe Newswire
2days ago
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition companies ("SPACs"): Skillsoft Corp. f/k/a Churchill Capital Corporation II (NYSE: SKIL), OppFi Inc. ...
Globe Newswire
11days ago
SAN DIEGO, Jan. 14, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition companies ("SPACs"): Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II (NYSE: KIND), ...
Ticker Report
2 months ago
Pardes Biosciences, Inc. (NASDAQ:PRDS Get Rating) Equities research analysts at SVB Leerink lifted their FY2024 EPS estimates for shares of Pardes Biosciences in a report issued on Monday, November 7th. SVB Leerink analyst R. Ruiz now forecasts that the company will post earnings per...
Globe Newswire
4 months ago
CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and ...
Zolmax
5 months ago
Pardes Biosciences (NASDAQ:PRDS Get Rating) had its price target dropped by investment analysts at SVB Leerink from $18.00 to $12.00 in a research report issued on Tuesday, MarketBeat.com reports. The firm presently has an outperform rating on the stock. SVB Leerinks price objective indicates a ...
Frequently Asked Questions
Frequently Asked Questions
What is Pardes Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Pardes Biosciences Inc shares?
plus_minus_icon
How can I buy Pardes Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Pardes Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Pardes Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Pardes Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Pardes Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Pardes Biosciences Inc?
plus_minus_icon
What percentage is Pardes Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Pardes Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.71
$-0.07
(-3.93%)
logo-prds
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00